Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Statins in lymphangioleiomyomatosis: a word of caution.

Literature DB >> 19648526

Statins in lymphangioleiomyomatosis: a word of caution.

S El-Chemaly, A Taveira-DaSilva, M P Stylianou, J Moss.

Abstract

Entities: CellLine Chemical Disease Gene Species

Mesh：

Substances：

Year: 2009 PMID： 19648526 PMCID： PMC2947144 DOI： 10.1183/09031936.00012709

Source DB: PubMed Journal: Eur Respir J ISSN： 0903-1936 Impact factor: 16.671

× No keyword cloud information.

6 in total

1. Doxycycline treatment for lymphangioleiomyomatosis with urinary monitoring for MMPs.

Authors: Marsha A Moses; Jay Harper; Judah Folkman
Journal: N Engl J Med Date: 2006-06-15 Impact factor: 91.245

Review 2. Statins and interstitial lung disease: a systematic review of the literature and of food and drug administration adverse event reports.

Authors: Antonio B Fernández; Richard H Karas; Alawi A Alsheikh-Ali; Paul D Thompson
Journal: Chest Date: 2008-08-08 Impact factor: 9.410

3. Decline in lung function in patients with lymphangioleiomyomatosis treated with or without progesterone.

Authors: Angelo M Taveira-DaSilva; Mario P Stylianou; Carolyn J Hedin; Olanda Hathaway; Joel Moss
Journal: Chest Date: 2004-12 Impact factor: 9.410

4. Angiogenic transcriptome of human microvascular endothelial cells: Effect of hypoxia, modulation by atorvastatin.

Authors: Agnieszka Loboda; Agnieszka Jazwa; Alicja Jozkowicz; Grietje Molema; Jozef Dulak
Journal: Vascul Pharmacol Date: 2006-02-14 Impact factor: 5.773

5. Selective inhibition of growth of tuberous sclerosis complex 2 null cells by atorvastatin is associated with impaired Rheb and Rho GTPase function and reduced mTOR/S6 kinase activity.

Authors: Geraldine A Finlay; Amy J Malhowski; Yingling Liu; Barry L Fanburg; David J Kwiatkowski; Deniz Toksoz
Journal: Cancer Res Date: 2007-10-15 Impact factor: 12.701

6. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis.

Authors: John J Bissler; Francis X McCormack; Lisa R Young; Jean M Elwing; Gail Chuck; Jennifer M Leonard; Vincent J Schmithorst; Tal Laor; Alan S Brody; Judy Bean; Shelia Salisbury; David N Franz
Journal: N Engl J Med Date: 2008-01-10 Impact factor: 91.245

6 in total

13 in total

1. Treatment option(s) for pulmonary lymphangioleiomyomatosis: progress and current challenges.

Authors: Vera P Krymskaya
Journal: Am J Respir Cell Mol Biol Date: 2012-05 Impact factor: 6.914

Review 2. Lymphangioleiomyomatosis: what do we know and what are we looking for?

Authors: S Harari; O Torre; J Moss
Journal: Eur Respir Rev Date: 2011-03

Review 3. Optimizing treatments for lymphangioleiomyomatosis.

Authors: Angelo M Taveira-DaSilva; Joel Moss
Journal: Expert Rev Respir Med Date: 2012-06 Impact factor: 3.772

Review 4. Lymphangioleiomyomatosis: New Treatment Perspectives.

Authors: Elżbieta Radzikowska
Journal: Lung Date: 2015-05-17 Impact factor: 2.584

5. Prevention of alveolar destruction and airspace enlargement in a mouse model of pulmonary lymphangioleiomyomatosis (LAM).

Authors: Elena A Goncharova; Dmitry A Goncharov; Melane Fehrenbach; Irene Khavin; Blerina Ducka; Okio Hino; Thomas V Colby; Mervyn J Merrilees; Angela Haczku; Steven M Albelda; Vera P Krymskaya
Journal: Sci Transl Med Date: 2012-10-03 Impact factor: 17.956

6. Retrospective review of combined sirolimus and simvastatin therapy in lymphangioleiomyomatosis.

Authors: Angelo M Taveira-DaSilva; Amanda M Jones; Patricia A Julien-Williams; Mario Stylianou; Joel Moss
Journal: Chest Date: 2015-01 Impact factor: 9.410

7. Statins in lymphangioleiomyomatosis. Simvastatin and atorvastatin induce differential effects on tuberous sclerosis complex 2-null cell growth and signaling.

Authors: Elena N Atochina-Vasserman; Dmitry A Goncharov; Alla V Volgina; Megan Milavec; Melane L James; Vera P Krymskaya
Journal: Am J Respir Cell Mol Biol Date: 2013-11 Impact factor: 6.914